|Articles|August 9, 2021
- Pharmaceutical Executive-08-01-2021
- Volume 41
- Issue 8
Pharmaceutical Executive, August 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive August 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 4 years ago
Why the Pandemic is Rewriting the Biopharma Rule Bookabout 4 years ago
Primary Care in Crisis: PCP Navigation in a Specialty Worldabout 4 years ago
A Brave New World: Optimizing Access in Wake of COVIDabout 4 years ago
By Any Genes Necessary: The Role of MEAs for Gene Therapiesabout 4 years ago
A Framework for Future: Strengthening Market Access Competenciesabout 4 years ago
A Global Vision for Accessabout 4 years ago
Early Payer-Related Lessons for Pharma Post-Aduhelm Approvalabout 4 years ago
Biotech Capital Markets Continue to UnderperformNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
